Company
Headquarters: Leipzig, Germany
Employees: 124
CEO: Dr. Wolfgang Knirsch
€77.7 Million
EUR as of July 1, 2024
US$83.5 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
VITA 34 AG engages in the collection, preparation, cryopreservation, and storage of stem cells from umbilical cord blood and tissue in Europe. The company offers Sibling Initiative that offers free storage of stem cells collected from the umbilical cord blood of a child whose brother or sister is seriously ill and needs the stem cells from the newborn sibling for treatment purposes; VitaPlusDonation that stores stem cells for personal therapeutic stem cell application; and VitaMine&Yours, which combines the storage of umbilical cord blood for personal provision with the possibility of a donation. It also provides Prevention screenings, which enable the detection of genetically related health risks and predispositions; and mobile stem cell team that facilitates the treatment with stem cells from umbilical cord blood in various hospitals. The company was founded in 1997 and is based in Leipzig, Germany.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
VITA 34 AG has the following listings and related stock indices.
Stock: XETR: V3V wb_incandescent
Stock: FSX: V3V wb_incandescent